,text,position,name,last,events,dateString,collapsed,checked
0,"<p>New funding applications are referred to one of Pharmac's Funding Application Advisors (FAAs), who'll review the application to ensure they have the relevant information to undertake a preliminary analysis.&nbsp; They may seek more information if required.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/</a></p>",0,Application Received,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jul 2022', 'fs': 'Jul 2022', 'change': None}, 'Event_Description': {'s': 'Application received', 'fs': 'Application received', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ00000FSxUL2A1'}, 'Id': 'a0POZ00000FSxUL2A1', 'Event_Date__c': '2022-07-16', 'Event_Description__c': 'Application received', 'Stage__c': 'Application Received', 'Formatted_Date__c': 'Jul 2022', 'Status_History__c': 'a132P000000Dv3eQAC'}, 'change': None}]",Jul 2022,False,True
1,"<p>Pharmac is identifying and gathering information required to get clinical advice.  The <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/"" rel=""nofollow"">Pharmacology and Therapeutics Advisory Committee (PTAC)</a>  meets quarterly. There are also around 20 expert <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/"" rel=""nofollow"">Specialist Advisory Committees (SACs)</a>, previously expert Subcommittees, which provide clinical evaluations in specialist areas. Specialist Advisory Committees meet as required to discuss issues referred to them by PTAC or Pharmac.</p>
<p style=""height: 20px"">&nbsp;</p>
<p>In November 2021, we introduced separate terms of reference for the SACs to make clear that these committees have different, but complementary, roles, expertise and perspectives to PTAC.</p>
<p style=""height: 15px"">&nbsp;</p>
<p>PTAC and SACs may make recommendations to Pharmac that differ from each other when looking at the same evidence. Pharmac considers the recommendations provided by all our clinical advisory committees when assessing applications.</p>
<p style=""height: 20px"">&nbsp;</p>
<p><a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/ptac-terms-of-reference-july-2021/"" rel=""nofollow"">PTAC</a>  and <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/specialist-advisory-committee-terms-of-reference//"" rel=""nofollow"">Specialist Advisory Committees</a> records of the meeting will be published on this website in accordance with the Terms of Reference.</p>",1,Seeking Clinical Advice,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jul 2022', 'fs': 'Jul 2022', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ00000FSxUM2A1'}, 'Id': 'a0POZ00000FSxUM2A1', 'Event_Date__c': '2022-07-20', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Jul 2022', 'Status_History__c': 'a132P000000Dv3jQAC'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Oct 2022', 'fs': 'Oct 2022', 'change': None}, 'Event_Description': {'s': 'Assigned to Cancer Treatments Advisory Committee meeting to provide advice on Friday 14 October 2022', 'fs': 'Assigned to Cancer Treatments Advisory Committee meeting to provide advice on Friday 14 October 2022', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ00000FSxUN2A1'}, 'Id': 'a0POZ00000FSxUN2A1', 'Event_Date__c': '2022-10-07', 'Event_Description__c': 'Assigned to Cancer Treatments Advisory Committee meeting to provide advice on Friday 14 October 2022', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Oct 2022', 'Status_History__c': 'a132P000000EDOzQAO'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that tislelizumab would be expected to provide the same health benefits for the second-line treatment of advanced non-small cell lung cancer (NSCLC) as other immune checkpoint inhibitors (ICIs) in this class for the second-line treatment of non-small cell lung cancer (NSCLC), and that that an agent in this class should be funded for the second line treatment of advanced non-small cell lung cancer.</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>In making this consideration, the Committee noted that the second-line clinical trial evidence for tislelizumab (including its statistical analyses) was not yet published or peer reviewed and considered its appraisal of the data was somewhat limited by this.</p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that CTAC should review new evidence when it eventuates regarding ICI retreatment for NSCLC (ie where progression did not occur while on ICI treatment) or regarding ICI treatment beyond progression in NSCLC.</p><p>1.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that that an ICI such as tislelizumab for second-line treatment of NSCLC should be funded according to the following criteria:</p><p><strong style=""font-size: 9pt;"">Initial application- (non-small cell lung cancer second line monotherapy)</strong><span style=""font-size: 9pt;""> only from a medical oncologist or any relevant practitioner on the recommendation of a medical oncologist. Approvals valid for 3 months for applications meeting the following criteria:</span></p><p><span style=""font-size: 9pt;"">All of the following:</span></p><p><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has locally advanced or metastatic non-small cell lung cancer; and</span></p><p><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has not received prior funded treatment with an immune checkpoint inhibitor for NSCLC; and</span></p><p><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">There is documentation confirming that the disease does not express activating mutations of EGFR or ALK tyrosine kinase unless not possible to ascertain; and</span></p><p><span style=""font-size: 9pt;"">4.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has an ECOG 0-2; and</span></p><p><span style=""font-size: 9pt;"">5.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has documented disease progression following treatment with at least two cycles of platinum-based chemotherapy; and</span></p><p><span style=""font-size: 9pt;"">6.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">XXXX is to be used as monotherapy at a dose of XXXXX every XXX weeks (or equivalent) for a maximum of 12 weeks; and</span></p><p><span style=""font-size: 9pt;"">7.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Baseline measurement of overall tumour burden is documented clinically and radiologically.</span></p><p><span style=""font-size: 9pt;"">\xa0</span></p><p><strong style=""font-size: 9pt;"">Renewal – (non-small cell lung cancer second line monotherapy</strong><span style=""font-size: 9pt;""> only from a medical oncologist or any relevant practitioner on the recommendation of a medical oncologist. Approvals valid for 3 months for applications meeting the following criteria:</span></p><p><span style=""font-size: 9pt;"">All of the following</span></p><p><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Any of the following:</span></p><p><span style=""font-size: 9pt;"">1.1.</span><span style=""font-size: 7pt;"">\xa0\xa0</span><span style=""font-size: 9pt;"">Patient’s disease has had a complete response to treatment; or</span></p><p><span style=""font-size: 9pt;"">1.2.</span><span style=""font-size: 7pt;"">\xa0\xa0</span><span style=""font-size: 9pt;"">Patient’s disease has had a partial response to treatment; or</span></p><p><span style=""font-size: 9pt;"">1.3.</span><span style=""font-size: 7pt;"">\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has stable disease; and</span></p><p><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Response to treatment in target lesions has been determined by comparable radiologic assessment following the most recent treatment period; and</span></p><p><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">No evidence of disease progression; and</span></p><p><span style=""font-size: 9pt;"">4.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">The treatment remains clinically appropriate and patient is benefitting from treatment; and</span></p><p><span style=""font-size: 9pt;"">5.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">XXXX to be used at a maximum dose of XXX every XXX weeks (or equivalent); and</span></p><p><span style=""font-size: 9pt;"">6.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">XXXX to be discontinued at signs of disease progression; and</span></p><p><span style=""font-size: 9pt;"">7.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Treatment with XXXX to cease after a total duration of 24 months from commencement (or equivalent).</span></p>', 'fs': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that tislelizumab would be expected to provide the same health benefits for the second-line treatment of advanced non-small cell lung cancer (NSCLC) as other immune checkpoint inhibitors (ICIs) in this class for the second-line treatment of non-small cell lung cancer (NSCLC), and that that an agent in this class should be funded for the second line treatment of advanced non-small cell lung cancer.</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>In making this consideration, the Committee noted that the second-line clinical trial evidence for tislelizumab (including its statistical analyses) was not yet published or peer reviewed and considered its appraisal of the data was somewhat limited by this.</p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that CTAC should review new evidence when it eventuates regarding ICI retreatment for NSCLC (ie where progression did not occur while on ICI treatment) or regarding ICI treatment beyond progression in NSCLC.</p><p>1.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that that an ICI such as tislelizumab for second-line treatment of NSCLC should be funded according to the following criteria:</p><p><strong style=""font-size: 9pt;"">Initial application- (non-small cell lung cancer second line monotherapy)</strong><span style=""font-size: 9pt;""> only from a medical oncologist or any relevant practitioner on the recommendation of a medical oncologist. Approvals valid for 3 months for applications meeting the following criteria:</span></p><p><span style=""font-size: 9pt;"">All of the following:</span></p><p><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has locally advanced or metastatic non-small cell lung cancer; and</span></p><p><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has not received prior funded treatment with an immune checkpoint inhibitor for NSCLC; and</span></p><p><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">There is documentation confirming that the disease does not express activating mutations of EGFR or ALK tyrosine kinase unless not possible to ascertain; and</span></p><p><span style=""font-size: 9pt;"">4.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has an ECOG 0-2; and</span></p><p><span style=""font-size: 9pt;"">5.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has documented disease progression following treatment with at least two cycles of platinum-based chemotherapy; and</span></p><p><span style=""font-size: 9pt;"">6.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">XXXX is to be used as monotherapy at a dose of XXXXX every XXX weeks (or equivalent) for a maximum of 12 weeks; and</span></p><p><span style=""font-size: 9pt;"">7.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Baseline measurement of overall tumour burden is documented clinically and radiologically.</span></p><p><span style=""font-size: 9pt;"">\xa0</span></p><p><strong style=""font-size: 9pt;"">Renewal – (non-small cell lung cancer second line monotherapy</strong><span style=""font-size: 9pt;""> only from a medical oncologist or any relevant practitioner on the recommendation of a medical oncologist. Approvals valid for 3 months for applications meeting the following criteria:</span></p><p><span style=""font-size: 9pt;"">All of the following</span></p><p><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Any of the following:</span></p><p><span style=""font-size: 9pt;"">1.1.</span><span style=""font-size: 7pt;"">\xa0\xa0</span><span style=""font-size: 9pt;"">Patient’s disease has had a complete response to treatment; or</span></p><p><span style=""font-size: 9pt;"">1.2.</span><span style=""font-size: 7pt;"">\xa0\xa0</span><span style=""font-size: 9pt;"">Patient’s disease has had a partial response to treatment; or</span></p><p><span style=""font-size: 9pt;"">1.3.</span><span style=""font-size: 7pt;"">\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has stable disease; and</span></p><p><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Response to treatment in target lesions has been determined by comparable radiologic assessment following the most recent treatment period; and</span></p><p><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">No evidence of disease progression; and</span></p><p><span style=""font-size: 9pt;"">4.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">The treatment remains clinically appropriate and patient is benefitting from treatment; and</span></p><p><span style=""font-size: 9pt;"">5.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">XXXX to be used at a maximum dose of XXX every XXX weeks (or equivalent); and</span></p><p><span style=""font-size: 9pt;"">6.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">XXXX to be discontinued at signs of disease progression; and</span></p><p><span style=""font-size: 9pt;"">7.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Treatment with XXXX to cease after a total duration of 24 months from commencement (or equivalent).</span></p>', 'change': None}, 'Published_Discussion': {'s': '<h3><em>Māori Impact</em></h3><p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that the disproportionate impact of advanced NSCLC for Māori had been described well in its previous considerations for agents for funding in this context. The Committee noted that Māori with any lung cancer have a very high health need and considered this was a particularly important gap to address.</p><h3><br></h3><h3><em>Background</em></h3><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the clinical advice and recommendations previously provided for the following ICIs for second-line treatment of NSCLC:</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://connect.pharmac.govt.nz/apptracker/s/application-public/a102P000008ptuw/p000243"" target=""_blank"">Atezolizumab (Tecentriq) for locally advanced or metastatic NSCLC after prior chemotherapy</a> (CaTSoP - Low August 2017; PTAC – Low August 2017)</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://connect.pharmac.govt.nz/apptracker/s/application-public/a102P000008puDw/p000793"" target=""_blank"">Nivolumab (Opdivo) for locally advanced or metastatic squamous and non-squamous NSCLC</a> (CaTSoP - Low/Medium April 2016; PTAC – Low May 2016)</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://connect.pharmac.govt.nz/apptracker/s/application-public/a102P000008puZ2/p001209"" target=""_blank"">Pembrolizumab (Keytruda) for locally advanced, or metastatic, unresectable NSCLC whose tumours express PD-L1 at a level of ≥ 1%</a> (PTAC – Low November 2016; CaTSoP – Low March 2017).</p><p>1.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the clinical trial evidence for each of these previously considered ICIs used docetaxel chemotherapy as a control and that this is the current standard of care in New Zealand for the second-line treatment of NSCLC.</p><h3><br></h3><h3><em>Health Need</em></h3><p>1.4.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the health need of this population and current treatment paradigm has been extensively discussed previously by PTAC and CTAC. Members considered that health need of this population remained very high and noted that international access to new treatments is increasing for all lines of NSCLC treatment.</p><p>1.5.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that Māori with any lung cancer have a very high health need, experiencing higher lung cancer registration and mortality rates than non-Māori, and considered this was a particularly important gap to address.</p><h3><br></h3><h3><em>Health Benefits and Suitability</em></h3><p>1.6.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that tislelizumab 100 mg/10mL concentrate for injection is currently being evaluated by Medsafe for oesophageal cancer and three NSCLC indications, including use as monotherapy for the treatment of patients with locally advanced or metastatic NSCLC after prior chemotherapy. The Committee noted that at the time of submission, the application was considered to meet Pharmac’s criteria for consideration under the <a href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/cancer-medicine-funding-parallel-assessment/"" target=""_blank"">parallel assessment</a> pathway, which provides for consideration of cancer medicines at the same time as they are assessed by Medsafe.</p><p>1.7.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the key evidence for tislelizumab for the second-line treatment of NSCLC comes from one key clinical trial, RATIONALE-303: a randomised (2:1), open-label, multi-centre, phase 3 study of 805 adults with histologically confirmed, locally advanced or metastatic NSCLC who had disease progression during or after a platinum-containing regimen. Participants received either tislelizumab 200 mg IV Q3W or docetaxel 75 mg/m2 IV Q3W until unacceptable toxicity or disease progression, and those in the tislelizumab arm had the option of subsequent tislelizumab 200 mg IV Q3W post-disease progression at the investigator’s discretion. The Committee noted that the following data from RATIONALE-303 was submitted for review:</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://ascopubs.org/doi/10.1200/JCO.2018.36.15_suppl.TPS3112"" target=""_blank"">Huang et al. J Clin Oncol. 2018; 36(15_Supplement)</a></p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://aacrjournals.org/cancerres/article/81/13_Supplement/CT039/669829/Abstract-CT039-Results-from-RATIONALE-303-A-global"" target=""_blank"">Zhou et al. Cancer Res. 2021; 81(13_Supplement):CT039</a></p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>RATIONALE-303 Clinical Study Report (CSR) 2022</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.beigenemedical.com/CongressDocuments/Zhou%20BGB-A317%20303%20PRO%20ASCO%20Poster%202021.pdf"" target=""_blank"">Zhou et al. J Clin Oncol. 2021;39(15_Supplement):9069</a></p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Fan et al. J Thorac Oncol. 2021;16:S1021</p><p>1.8.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that 80% of RATIONALE-303 participants were from China and that 14 (&lt;2%) of patients were enrolled in New Zealand. The Committee considered that patient characteristics were similar across treatment groups and although there were differences between the trial patient populations, it was not unreasonable to compare with the results of the second-line trials for atezolizumab, nivolumab and pembrolizumab. The Committee noted that about half of the RATIONALE-303 participants had non-squamous NSCLC and that large proportions of patients had unknown EGFR mutation (&gt;30%) or ALK rearrangement (&gt;50%) status. The Committee noted that for 15% of patients the trial treatment was a third-line therapy (ie had received two prior lines) and that disease progression was the most common reason for trial treatment discontinuation.</p><p>1.9.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the primary endpoint of RATIONALE-303 was overall survival (OS) in the intention-to-treat (ITT) and PD-L1 positive (≥25%) populations, which was reported after median 31.1 months and 27.9 months follow-up for the tislelizumab and docetaxel arms, respectively.</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the median OS in the ITT group was 16.9 months (95% CI: 15.24 to 19.09 months) with tislelizumab compared with 11.9 months (95% CI: 9.6 to 13.54 months) with docetaxel; hazard ratio (HR) for death: 0.66 (95% CI: 0.56 to 0.79; P&lt;0.0001). The Committee noted that the OS benefit with docetaxel appeared slightly better than that seen in the control arm of the studies previously considered for other ICIs for this indication, however, considered that this difference might be due to improvements in patient care and management of adverse events occurring in the years since the trials were initiated.</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that 29.5% of patients in the tislelizumab arm continued tislelizumab after radiographic progression, and that 20.4% of patients in the docetaxel arm subsequently received immunotherapy. The Committee considered that, although occurring in large proportions, this crossover and treatment beyond progression was unlikely to have a material impact on survival outcomes given the benefit seen despite the crossover. Members noted that the duration of treatment beyond progression was unknown but considered that in this disease, patients generally become symptomatic in a short time and then discontinue such treatment.</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that median OS in the PD-L1 positive group was 19.3 months with tislelizumab compared with 11.5 months with docetaxel; HR 0.53 (95% CI: 0.404 to 0.696; P&lt;0.0001). The Committee noted that the study assessed different PD-L1 thresholds and that the results indicated that all participants received a benefit regardless of PD-L1 expression.</p><p>1.10.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the duration of response (DOR) in the RATIONALE-303 ITT population, a secondary outcome, was a median of 13.5 months (95% CI: 8.54 to 19.58 months) with tislelizumab compared with 6.0 months (95% CI: 2.10 to 7.16 months) with docetaxel (HR 0.31; 95% CI: 0.176 to 0.536; P&lt;0.0001). The Committee considered this to be an important outcome for patients because a durable benefit leads to long-term benefits.</p><p>1.11.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the median progression-free survival (PFS) in RATIONALE-303 was 4.2 months (95% CI: 3.88 to 22.6 months) with tislelizumab compared with 2.6 months (95% CI: 2.2 to 3.8 months) with docetaxel; HR: 0.63 (95% CI: 0.53 to 0.75).</p><p>1.12.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that treatment-emergent adverse events led to discontinuation in about 12% of RATIONALE-303 participants in each arm. The Committee considered that there was a relatively high rate of grade three or higher immune-related adverse events (irAEs) in the tislelizumab arm, however, members considered this was similar to what would be expected based on the evidence and experience with other ICIs. The Committee noted that there were no new irAE signals with tislelizumab.</p><p>1.13.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the second-line clinical trial evidence for tislelizumab from RATIONALE-303 (including its statistical analyses) was not yet published or peer reviewed and considered its appraisal of the data was somewhat limited by this, however, the Committee considered this status was not surprising given that trial completion is expected in December 2022.</p><p>1.14.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted a cost-effectiveness analysis of tislelizumab relative to each nivolumab and docetaxel, as second- and third-line for advanced or metastatic non-small cell lung cancer in China (<a href=""https://www.frontiersin.org/articles/10.3389/fphar.2022.880280/full"" target=""_blank"">Zhou et al. Front Pharmacol. 2022;13:880280</a>), and was made aware of another cost-effectiveness analysis of tislelizumab vs docetaxel for previously treated NSCLC in China (<a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/35614942/"" target=""_blank"">Gong et al. Front Pharmacol. 2022;13:830380</a>).</p><p>1.15.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted there is longer-term evidence now published from the clinical trials previously considered for second-line use of atezolizumab, nivolumab, and pembrolizumab. The Committee noted that the pembrolizumab KEYNOTE-010 trial included a more limited population (PD-L1 positive ≥1%) than that of the other trials which did not restrict eligibility to PD-L1 positive participants. The Committee noted that across these trials there were small proportions of patients with EGFR mutations or ALK rearrangement, that about a third had ECOG performance status of zero, and that 75-80% were receiving trial treatment as a second-line therapy. The Committee considered that the longer-term evidence from these trials showed similar PFS, OS and durable benefits and reinforced the impression of the class effect consideration with these ICIs in the first-line treatment of NSCLC:</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.jto.org/article/S1556-0864(20)30802-9/fulltext"" target=""_blank"">Mazieres et al. J Thorac Oncol. 2021;16:140-50</a> - After 47.7 months follow-up in the Oak trial, the median OS was 13.3 months with atezolizumab vs 9.8 months with docetaxel; HR 0.78 (0.68 to 0.89; P&lt;0.0001).</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8078445/"" target=""_blank"">Borghaei et al. J Clin Oncol. 2021;39:723-33</a> – After 64.2 and 64.5 months follow-up in the Checkmate 057 and 017 trials, respectively, the median pooled OS for squamous and non-squamous 9.2 months (95% CI: 7.3 to 12.6) with nivolumab vs 6.0 months (95% CI: 5.1 to 7.3) with docetaxel; HR 0.62 (95% CI: 0.48 to 0.79).</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.sciencedirect.com/science/article/abs/pii/S1556086421021729"" target=""_blank"">Herbst et al. J Thorac Oncol. 2021;16:1718-32</a><em> </em>– After 67.4 months follow-up in KEYNOTE-010, the median OS was 11.8 months (95% CI: 10.4 to 13.1) with pembrolizumab vs 8.4 months (95% CI: 7.6 to 9.5) with docetaxel; HR for death 0.70 (95% CI: 0.61–0.80). 21 patients received second-course pembrolizumab and there was 22.2% crossover in the docetaxel arm.\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</p><p>1.16.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that there were no direct comparisons of ICIs for second-line treatment of NSCLC but considered that the evidence reported relatively consistent OS improvement across trials with these ICIs despite some differences in the patient populations within the trials. The Committee further considered that there was no evidence to suggest any ICI might be better tolerated or more efficacious than any other, and therefore a class effect was likely to exist for these ICIs including tislelizumab based on the evidence available in this setting. The Committee considered that tislelizumab would have similar ability to address the unmet need in New Zealand for the second-line use of an ICI and that the evidence for tislelizumab’s safety profile also suggested a class effect.</p><p>1.17.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that tislelizumab would not be expected to provide any additional health benefits or create any additional risks compared with other ICIs (ie atezolizumab, nivolumab and pembrolizumab) considered for second-line treatment of advanced NSCLC. The Committee noted that a similar duration of treatment, similar side effects and considered that a similar frequency of treatment would be expected.</p><p>1.18.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the three-weekly frequency of tislelizumab treatment and considered that this may differ from that of other ICIs for second-line treatment of advanced NSCLC which may also have options for longer dosing intervals (eg four- or six-weekly). The Committee was made aware of evidence for longer dosing intervals of pembrolizumab from pharmacology modelling and international guidelines in response to the COVID-19 pandemic (<a href=""https://linkinghub.elsevier.com/retrieve/pii/S1556-0864(22)00314-8"" target=""_blank"">Higashiyama et al. J Thorac Oncol. 2022;17:1227-32</a>; <a href=""https://linkinghub.elsevier.com/retrieve/pii/S1556-0864(22)00347-1"" target=""_blank"">Mountzios et al. J Thorac Oncol. 2022;17:1155-7</a>). Members noted the number of patients who experienced new irAEs was slightly higher than expected although considered it unclear whether this was caused by the dosing interval change as this as it was not a controlled trial, and on balance, considered the dosing intervals likely to be safe. The Committee considered that the impact on the health system would be determined by the chosen ICI and the level of comfort with using different dosing schedules.</p><p>1.19.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the stability of the ICI solutions for infusion (once diluted, if applicable) at 2-8°C ranged from 24 hours for tislelizumab and atezolizumab to four or seven days for pembrolizumab and nivolumab, respectively. The Committee considered that the ease of treatment delivery differed between these ICIs and that these could be important factors for New Zealanders in regard to inequities and access to treatment, particularly those living in rural areas.</p><p>1.20.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered it reasonable to have a maximum funded treatment duration of 24 months with an option to have ICI retreatment where no progression occurred while on ICI treatment, noting that most clinical trials with a two-year ICI treatment duration include an option for retreatment. Members considered that it would be difficult to delineate whether people with NSCLC receiving retreatment would be considered to have first- or second-line treatment as clinically this might be approached as first-line with late progression, indicating a good response to first-line treatment.</p><p>1.21.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that CTAC should review new evidence when it eventuates regarding ICI retreatment for NSCLC (ie where progression did not occur while on ICI treatment) or regarding ICI treatment beyond progression in NSCLC. The Committee acknowledged its previous view regarding this may be amenable to newer information becoming available to support retreatment or treatment beyond progression. The Committee noted that at this time, the evidence supporting retreatment came from small numbers of patients who initially received 24 months of pembrolizumab and were then retreated post-progression in the KEYNOTE-010 trial (<a href=""https://ascopubs.org/doi/10.1200/JCO.19.02446?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub%20%200pubmed"" target=""_blank"">Herbst et al. J Clin Oncol. 2020;38:1580-90</a>) or patients who received 12 months of durvalumab and then treatment with durvalumab at progression in the PACIFIC trial (<a href=""https://ascopubs.org/doi/10.1200/JCO.21.01308?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub%20%200pubmed"" target=""_blank"">Spigel et al. J Clin Oncol. 2022;40:1301-11</a>).</p><h3><br></h3><h3><em>Costs and Savings</em></h3><p>1.22.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that if an ICI were funded for both first- and second-line treatment of NSCLC (but as a single line of treatment), that initially a large number of individuals would receive this as second-line ICI treatment, although this would reduce over time as first-line ICI therapy became common. The Committee considered that changes in health-sector expenditure with tislelizumab would be comparable to those with other ICIs for second-line treatment of advanced NSCLC but that there could be wastage associated with the reduced stability of tislelizumab as currently stated.</p><p>1.23.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that a two-year maximum treatment duration was appropriate to include in the PICO for assessment, noting its previous comments regarding the option for retreatment in only a small number of patients.</p><h3><br></h3><h3><em>Special Authority Criteria</em></h3><p>1.24.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that Special Authority criteria for an ICI (such as tislelizumab) for second-line treatment of NSCLC should:</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Target individuals with ECOG performance status of zero to two instead of zero to one, as most have ECOG of two after progression and would be considered able to tolerate this treatment.</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Not require documentation confirming that the disease does not express activating mutations of EGFR or ALK as this might create a barrier to access due to reliance on biopsy for tissue testing, and that such a criterion should be pragmatic and equitable.</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Omit the requirement for the use of RECIST for assessment, as this onerous assessment is difficult to do in the current health system constraints. Members considered that RECIST is not an ideal measure for lung tumour burden, that radiologist availability and cost are factors which can create barriers, and that it is challenging to have consistent assessment. However, the Committee noted the need to document disease burden at baseline to enable subsequent assessment.</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Require confirmation that there is no evidence of disease progression at renewal, and that it would be important that the same modality was used to establish response to treatment.</p><h3><br></h3><h3><em>Summary for Assessment</em></h3><p>1.25.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that the evidence for tislelizumab as second-line treatment of NSCLC was limited but not poor and that, for the purposes of economic modelling, it would be appropriate to assume that tislelizumab provided the same or similar health benefit to other agents currently under consideration.</p><p>1.26.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that the proportion of people who receive docetaxel in the second- and third-line setting was likely to be closer to 30%, rather than the current estimate of 50%.</p><p>1.27.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that the table below summarises its interpretation of the most appropriate PICO (population, intervention, comparator, outcomes) information for tislelizumab if it were to be funded in New Zealand for second-line treatment of NSCLC. This PICO captures key clinical aspects of the proposal and may be used to frame any future economic assessment by Pharmac staff. This PICO is based on the Committee’s assessment at this time and may differ from that requested by the applicant. The PICO may change based on new information, additional clinical advice, or further analysis by Pharmac staff.\xa0\xa0</p><p><img src=""/apptracker/servlet/rtaImage?eid=a0POZ00000FSxUO&amp;feoid=00N2P000000YsIc&amp;refid=0EM2P000002eNWd"" alt=""image.png""></img></p>', 'fs': '<h3><em>Māori Impact</em></h3><p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that the disproportionate impact of advanced NSCLC for Māori had been described well in its previous considerations for agents for funding in this context. The Committee noted that Māori with any lung cancer have a very high health need and considered this was a particularly important gap to address.</p><h3><br></h3><h3><em>Background</em></h3><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the clinical advice and recommendations previously provided for the following ICIs for second-line treatment of NSCLC:</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://connect.pharmac.govt.nz/apptracker/s/application-public/a102P000008ptuw/p000243"" target=""_blank"">Atezolizumab (Tecentriq) for locally advanced or metastatic NSCLC after prior chemotherapy</a> (CaTSoP - Low August 2017; PTAC – Low August 2017)</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://connect.pharmac.govt.nz/apptracker/s/application-public/a102P000008puDw/p000793"" target=""_blank"">Nivolumab (Opdivo) for locally advanced or metastatic squamous and non-squamous NSCLC</a> (CaTSoP - Low/Medium April 2016; PTAC – Low May 2016)</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://connect.pharmac.govt.nz/apptracker/s/application-public/a102P000008puZ2/p001209"" target=""_blank"">Pembrolizumab (Keytruda) for locally advanced, or metastatic, unresectable NSCLC whose tumours express PD-L1 at a level of ≥ 1%</a> (PTAC – Low November 2016; CaTSoP – Low March 2017).</p><p>1.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the clinical trial evidence for each of these previously considered ICIs used docetaxel chemotherapy as a control and that this is the current standard of care in New Zealand for the second-line treatment of NSCLC.</p><h3><br></h3><h3><em>Health Need</em></h3><p>1.4.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the health need of this population and current treatment paradigm has been extensively discussed previously by PTAC and CTAC. Members considered that health need of this population remained very high and noted that international access to new treatments is increasing for all lines of NSCLC treatment.</p><p>1.5.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that Māori with any lung cancer have a very high health need, experiencing higher lung cancer registration and mortality rates than non-Māori, and considered this was a particularly important gap to address.</p><h3><br></h3><h3><em>Health Benefits and Suitability</em></h3><p>1.6.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that tislelizumab 100 mg/10mL concentrate for injection is currently being evaluated by Medsafe for oesophageal cancer and three NSCLC indications, including use as monotherapy for the treatment of patients with locally advanced or metastatic NSCLC after prior chemotherapy. The Committee noted that at the time of submission, the application was considered to meet Pharmac’s criteria for consideration under the <a href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/cancer-medicine-funding-parallel-assessment/"" target=""_blank"">parallel assessment</a> pathway, which provides for consideration of cancer medicines at the same time as they are assessed by Medsafe.</p><p>1.7.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the key evidence for tislelizumab for the second-line treatment of NSCLC comes from one key clinical trial, RATIONALE-303: a randomised (2:1), open-label, multi-centre, phase 3 study of 805 adults with histologically confirmed, locally advanced or metastatic NSCLC who had disease progression during or after a platinum-containing regimen. Participants received either tislelizumab 200 mg IV Q3W or docetaxel 75 mg/m2 IV Q3W until unacceptable toxicity or disease progression, and those in the tislelizumab arm had the option of subsequent tislelizumab 200 mg IV Q3W post-disease progression at the investigator’s discretion. The Committee noted that the following data from RATIONALE-303 was submitted for review:</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://ascopubs.org/doi/10.1200/JCO.2018.36.15_suppl.TPS3112"" target=""_blank"">Huang et al. J Clin Oncol. 2018; 36(15_Supplement)</a></p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://aacrjournals.org/cancerres/article/81/13_Supplement/CT039/669829/Abstract-CT039-Results-from-RATIONALE-303-A-global"" target=""_blank"">Zhou et al. Cancer Res. 2021; 81(13_Supplement):CT039</a></p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>RATIONALE-303 Clinical Study Report (CSR) 2022</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.beigenemedical.com/CongressDocuments/Zhou%20BGB-A317%20303%20PRO%20ASCO%20Poster%202021.pdf"" target=""_blank"">Zhou et al. J Clin Oncol. 2021;39(15_Supplement):9069</a></p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Fan et al. J Thorac Oncol. 2021;16:S1021</p><p>1.8.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that 80% of RATIONALE-303 participants were from China and that 14 (&lt;2%) of patients were enrolled in New Zealand. The Committee considered that patient characteristics were similar across treatment groups and although there were differences between the trial patient populations, it was not unreasonable to compare with the results of the second-line trials for atezolizumab, nivolumab and pembrolizumab. The Committee noted that about half of the RATIONALE-303 participants had non-squamous NSCLC and that large proportions of patients had unknown EGFR mutation (&gt;30%) or ALK rearrangement (&gt;50%) status. The Committee noted that for 15% of patients the trial treatment was a third-line therapy (ie had received two prior lines) and that disease progression was the most common reason for trial treatment discontinuation.</p><p>1.9.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the primary endpoint of RATIONALE-303 was overall survival (OS) in the intention-to-treat (ITT) and PD-L1 positive (≥25%) populations, which was reported after median 31.1 months and 27.9 months follow-up for the tislelizumab and docetaxel arms, respectively.</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the median OS in the ITT group was 16.9 months (95% CI: 15.24 to 19.09 months) with tislelizumab compared with 11.9 months (95% CI: 9.6 to 13.54 months) with docetaxel; hazard ratio (HR) for death: 0.66 (95% CI: 0.56 to 0.79; P&lt;0.0001). The Committee noted that the OS benefit with docetaxel appeared slightly better than that seen in the control arm of the studies previously considered for other ICIs for this indication, however, considered that this difference might be due to improvements in patient care and management of adverse events occurring in the years since the trials were initiated.</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that 29.5% of patients in the tislelizumab arm continued tislelizumab after radiographic progression, and that 20.4% of patients in the docetaxel arm subsequently received immunotherapy. The Committee considered that, although occurring in large proportions, this crossover and treatment beyond progression was unlikely to have a material impact on survival outcomes given the benefit seen despite the crossover. Members noted that the duration of treatment beyond progression was unknown but considered that in this disease, patients generally become symptomatic in a short time and then discontinue such treatment.</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that median OS in the PD-L1 positive group was 19.3 months with tislelizumab compared with 11.5 months with docetaxel; HR 0.53 (95% CI: 0.404 to 0.696; P&lt;0.0001). The Committee noted that the study assessed different PD-L1 thresholds and that the results indicated that all participants received a benefit regardless of PD-L1 expression.</p><p>1.10.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the duration of response (DOR) in the RATIONALE-303 ITT population, a secondary outcome, was a median of 13.5 months (95% CI: 8.54 to 19.58 months) with tislelizumab compared with 6.0 months (95% CI: 2.10 to 7.16 months) with docetaxel (HR 0.31; 95% CI: 0.176 to 0.536; P&lt;0.0001). The Committee considered this to be an important outcome for patients because a durable benefit leads to long-term benefits.</p><p>1.11.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the median progression-free survival (PFS) in RATIONALE-303 was 4.2 months (95% CI: 3.88 to 22.6 months) with tislelizumab compared with 2.6 months (95% CI: 2.2 to 3.8 months) with docetaxel; HR: 0.63 (95% CI: 0.53 to 0.75).</p><p>1.12.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that treatment-emergent adverse events led to discontinuation in about 12% of RATIONALE-303 participants in each arm. The Committee considered that there was a relatively high rate of grade three or higher immune-related adverse events (irAEs) in the tislelizumab arm, however, members considered this was similar to what would be expected based on the evidence and experience with other ICIs. The Committee noted that there were no new irAE signals with tislelizumab.</p><p>1.13.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the second-line clinical trial evidence for tislelizumab from RATIONALE-303 (including its statistical analyses) was not yet published or peer reviewed and considered its appraisal of the data was somewhat limited by this, however, the Committee considered this status was not surprising given that trial completion is expected in December 2022.</p><p>1.14.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted a cost-effectiveness analysis of tislelizumab relative to each nivolumab and docetaxel, as second- and third-line for advanced or metastatic non-small cell lung cancer in China (<a href=""https://www.frontiersin.org/articles/10.3389/fphar.2022.880280/full"" target=""_blank"">Zhou et al. Front Pharmacol. 2022;13:880280</a>), and was made aware of another cost-effectiveness analysis of tislelizumab vs docetaxel for previously treated NSCLC in China (<a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/35614942/"" target=""_blank"">Gong et al. Front Pharmacol. 2022;13:830380</a>).</p><p>1.15.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted there is longer-term evidence now published from the clinical trials previously considered for second-line use of atezolizumab, nivolumab, and pembrolizumab. The Committee noted that the pembrolizumab KEYNOTE-010 trial included a more limited population (PD-L1 positive ≥1%) than that of the other trials which did not restrict eligibility to PD-L1 positive participants. The Committee noted that across these trials there were small proportions of patients with EGFR mutations or ALK rearrangement, that about a third had ECOG performance status of zero, and that 75-80% were receiving trial treatment as a second-line therapy. The Committee considered that the longer-term evidence from these trials showed similar PFS, OS and durable benefits and reinforced the impression of the class effect consideration with these ICIs in the first-line treatment of NSCLC:</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.jto.org/article/S1556-0864(20)30802-9/fulltext"" target=""_blank"">Mazieres et al. J Thorac Oncol. 2021;16:140-50</a> - After 47.7 months follow-up in the Oak trial, the median OS was 13.3 months with atezolizumab vs 9.8 months with docetaxel; HR 0.78 (0.68 to 0.89; P&lt;0.0001).</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8078445/"" target=""_blank"">Borghaei et al. J Clin Oncol. 2021;39:723-33</a> – After 64.2 and 64.5 months follow-up in the Checkmate 057 and 017 trials, respectively, the median pooled OS for squamous and non-squamous 9.2 months (95% CI: 7.3 to 12.6) with nivolumab vs 6.0 months (95% CI: 5.1 to 7.3) with docetaxel; HR 0.62 (95% CI: 0.48 to 0.79).</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.sciencedirect.com/science/article/abs/pii/S1556086421021729"" target=""_blank"">Herbst et al. J Thorac Oncol. 2021;16:1718-32</a><em> </em>– After 67.4 months follow-up in KEYNOTE-010, the median OS was 11.8 months (95% CI: 10.4 to 13.1) with pembrolizumab vs 8.4 months (95% CI: 7.6 to 9.5) with docetaxel; HR for death 0.70 (95% CI: 0.61–0.80). 21 patients received second-course pembrolizumab and there was 22.2% crossover in the docetaxel arm.\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</p><p>1.16.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that there were no direct comparisons of ICIs for second-line treatment of NSCLC but considered that the evidence reported relatively consistent OS improvement across trials with these ICIs despite some differences in the patient populations within the trials. The Committee further considered that there was no evidence to suggest any ICI might be better tolerated or more efficacious than any other, and therefore a class effect was likely to exist for these ICIs including tislelizumab based on the evidence available in this setting. The Committee considered that tislelizumab would have similar ability to address the unmet need in New Zealand for the second-line use of an ICI and that the evidence for tislelizumab’s safety profile also suggested a class effect.</p><p>1.17.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that tislelizumab would not be expected to provide any additional health benefits or create any additional risks compared with other ICIs (ie atezolizumab, nivolumab and pembrolizumab) considered for second-line treatment of advanced NSCLC. The Committee noted that a similar duration of treatment, similar side effects and considered that a similar frequency of treatment would be expected.</p><p>1.18.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the three-weekly frequency of tislelizumab treatment and considered that this may differ from that of other ICIs for second-line treatment of advanced NSCLC which may also have options for longer dosing intervals (eg four- or six-weekly). The Committee was made aware of evidence for longer dosing intervals of pembrolizumab from pharmacology modelling and international guidelines in response to the COVID-19 pandemic (<a href=""https://linkinghub.elsevier.com/retrieve/pii/S1556-0864(22)00314-8"" target=""_blank"">Higashiyama et al. J Thorac Oncol. 2022;17:1227-32</a>; <a href=""https://linkinghub.elsevier.com/retrieve/pii/S1556-0864(22)00347-1"" target=""_blank"">Mountzios et al. J Thorac Oncol. 2022;17:1155-7</a>). Members noted the number of patients who experienced new irAEs was slightly higher than expected although considered it unclear whether this was caused by the dosing interval change as this as it was not a controlled trial, and on balance, considered the dosing intervals likely to be safe. The Committee considered that the impact on the health system would be determined by the chosen ICI and the level of comfort with using different dosing schedules.</p><p>1.19.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the stability of the ICI solutions for infusion (once diluted, if applicable) at 2-8°C ranged from 24 hours for tislelizumab and atezolizumab to four or seven days for pembrolizumab and nivolumab, respectively. The Committee considered that the ease of treatment delivery differed between these ICIs and that these could be important factors for New Zealanders in regard to inequities and access to treatment, particularly those living in rural areas.</p><p>1.20.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered it reasonable to have a maximum funded treatment duration of 24 months with an option to have ICI retreatment where no progression occurred while on ICI treatment, noting that most clinical trials with a two-year ICI treatment duration include an option for retreatment. Members considered that it would be difficult to delineate whether people with NSCLC receiving retreatment would be considered to have first- or second-line treatment as clinically this might be approached as first-line with late progression, indicating a good response to first-line treatment.</p><p>1.21.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that CTAC should review new evidence when it eventuates regarding ICI retreatment for NSCLC (ie where progression did not occur while on ICI treatment) or regarding ICI treatment beyond progression in NSCLC. The Committee acknowledged its previous view regarding this may be amenable to newer information becoming available to support retreatment or treatment beyond progression. The Committee noted that at this time, the evidence supporting retreatment came from small numbers of patients who initially received 24 months of pembrolizumab and were then retreated post-progression in the KEYNOTE-010 trial (<a href=""https://ascopubs.org/doi/10.1200/JCO.19.02446?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub%20%200pubmed"" target=""_blank"">Herbst et al. J Clin Oncol. 2020;38:1580-90</a>) or patients who received 12 months of durvalumab and then treatment with durvalumab at progression in the PACIFIC trial (<a href=""https://ascopubs.org/doi/10.1200/JCO.21.01308?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub%20%200pubmed"" target=""_blank"">Spigel et al. J Clin Oncol. 2022;40:1301-11</a>).</p><h3><br></h3><h3><em>Costs and Savings</em></h3><p>1.22.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that if an ICI were funded for both first- and second-line treatment of NSCLC (but as a single line of treatment), that initially a large number of individuals would receive this as second-line ICI treatment, although this would reduce over time as first-line ICI therapy became common. The Committee considered that changes in health-sector expenditure with tislelizumab would be comparable to those with other ICIs for second-line treatment of advanced NSCLC but that there could be wastage associated with the reduced stability of tislelizumab as currently stated.</p><p>1.23.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that a two-year maximum treatment duration was appropriate to include in the PICO for assessment, noting its previous comments regarding the option for retreatment in only a small number of patients.</p><h3><br></h3><h3><em>Special Authority Criteria</em></h3><p>1.24.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that Special Authority criteria for an ICI (such as tislelizumab) for second-line treatment of NSCLC should:</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Target individuals with ECOG performance status of zero to two instead of zero to one, as most have ECOG of two after progression and would be considered able to tolerate this treatment.</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Not require documentation confirming that the disease does not express activating mutations of EGFR or ALK as this might create a barrier to access due to reliance on biopsy for tissue testing, and that such a criterion should be pragmatic and equitable.</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Omit the requirement for the use of RECIST for assessment, as this onerous assessment is difficult to do in the current health system constraints. Members considered that RECIST is not an ideal measure for lung tumour burden, that radiologist availability and cost are factors which can create barriers, and that it is challenging to have consistent assessment. However, the Committee noted the need to document disease burden at baseline to enable subsequent assessment.</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Require confirmation that there is no evidence of disease progression at renewal, and that it would be important that the same modality was used to establish response to treatment.</p><h3><br></h3><h3><em>Summary for Assessment</em></h3><p>1.25.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that the evidence for tislelizumab as second-line treatment of NSCLC was limited but not poor and that, for the purposes of economic modelling, it would be appropriate to assume that tislelizumab provided the same or similar health benefit to other agents currently under consideration.</p><p>1.26.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that the proportion of people who receive docetaxel in the second- and third-line setting was likely to be closer to 30%, rather than the current estimate of 50%.</p><p>1.27.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that the table below summarises its interpretation of the most appropriate PICO (population, intervention, comparator, outcomes) information for tislelizumab if it were to be funded in New Zealand for second-line treatment of NSCLC. This PICO captures key clinical aspects of the proposal and may be used to frame any future economic assessment by Pharmac staff. This PICO is based on the Committee’s assessment at this time and may differ from that requested by the applicant. The PICO may change based on new information, additional clinical advice, or further analysis by Pharmac staff.\xa0\xa0</p><p><img src=""/apptracker/servlet/rtaImage?eid=a0POZ00000FSxUO&amp;feoid=00N2P000000YsIc&amp;refid=0EM2P000002eNWd"" alt=""image.png""></img></p>', 'change': None}, 'Published_Application': {'s': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee reviewed the application from BeiGene NZ Unlimited for the use of tislelizumab (Tevimbra) for the second-line treatment of non-small cell lung cancer (NSCLC) which was received in response to Pharmac’s 2022 Request For Proposals (RFP) for immune checkpoint inhibitors (ICIs).</p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that Pharmac staff sought advice in the context of this RFP for ICIs for advanced NSCLC, noting that Pharmac has received previous advice regarding atezolizumab, nivolumab and pembrolizumab in this setting.</p><p>1.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee took into account, where applicable, Pharmac’s relevant decision-making framework when considering this agenda item.\xa0</p>', 'fs': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee reviewed the application from BeiGene NZ Unlimited for the use of tislelizumab (Tevimbra) for the second-line treatment of non-small cell lung cancer (NSCLC) which was received in response to Pharmac’s 2022 Request For Proposals (RFP) for immune checkpoint inhibitors (ICIs).</p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that Pharmac staff sought advice in the context of this RFP for ICIs for advanced NSCLC, noting that Pharmac has received previous advice regarding atezolizumab, nivolumab and pembrolizumab in this setting.</p><p>1.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee took into account, where applicable, Pharmac’s relevant decision-making framework when considering this agenda item.\xa0</p>', 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'No Formal Recommendation', 'fs': 'No Formal Recommendation', 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Feb 2023', 'fs': 'Feb 2023', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Cancer Treatments Advisory Committee at meeting Friday 14 October 2022.', 'fs': 'Clinical advice received from Cancer Treatments Advisory Committee at meeting Friday 14 October 2022.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ00000FSxUO2A1'}, 'Id': 'a0POZ00000FSxUO2A1', 'Event_Date__c': '2023-02-13', 'Event_Description__c': 'Clinical advice received from Cancer Treatments Advisory Committee at meeting Friday 14 October 2022.', 'Stage__c': 'Seeking Clinical Advice', 'Outcome__c': 'No Formal Recommendation', 'Formatted_Date__c': 'Feb 2023', 'Published_Recommendation__c': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that tislelizumab would be expected to provide the same health benefits for the second-line treatment of advanced non-small cell lung cancer (NSCLC) as other immune checkpoint inhibitors (ICIs) in this class for the second-line treatment of non-small cell lung cancer (NSCLC), and that that an agent in this class should be funded for the second line treatment of advanced non-small cell lung cancer.</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>In making this consideration, the Committee noted that the second-line clinical trial evidence for tislelizumab (including its statistical analyses) was not yet published or peer reviewed and considered its appraisal of the data was somewhat limited by this.</p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that CTAC should review new evidence when it eventuates regarding ICI retreatment for NSCLC (ie where progression did not occur while on ICI treatment) or regarding ICI treatment beyond progression in NSCLC.</p><p>1.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that that an ICI such as tislelizumab for second-line treatment of NSCLC should be funded according to the following criteria:</p><p><strong style=""font-size: 9pt;"">Initial application- (non-small cell lung cancer second line monotherapy)</strong><span style=""font-size: 9pt;""> only from a medical oncologist or any relevant practitioner on the recommendation of a medical oncologist. Approvals valid for 3 months for applications meeting the following criteria:</span></p><p><span style=""font-size: 9pt;"">All of the following:</span></p><p><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has locally advanced or metastatic non-small cell lung cancer; and</span></p><p><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has not received prior funded treatment with an immune checkpoint inhibitor for NSCLC; and</span></p><p><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">There is documentation confirming that the disease does not express activating mutations of EGFR or ALK tyrosine kinase unless not possible to ascertain; and</span></p><p><span style=""font-size: 9pt;"">4.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has an ECOG 0-2; and</span></p><p><span style=""font-size: 9pt;"">5.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has documented disease progression following treatment with at least two cycles of platinum-based chemotherapy; and</span></p><p><span style=""font-size: 9pt;"">6.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">XXXX is to be used as monotherapy at a dose of XXXXX every XXX weeks (or equivalent) for a maximum of 12 weeks; and</span></p><p><span style=""font-size: 9pt;"">7.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Baseline measurement of overall tumour burden is documented clinically and radiologically.</span></p><p><span style=""font-size: 9pt;"">\xa0</span></p><p><strong style=""font-size: 9pt;"">Renewal – (non-small cell lung cancer second line monotherapy</strong><span style=""font-size: 9pt;""> only from a medical oncologist or any relevant practitioner on the recommendation of a medical oncologist. Approvals valid for 3 months for applications meeting the following criteria:</span></p><p><span style=""font-size: 9pt;"">All of the following</span></p><p><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Any of the following:</span></p><p><span style=""font-size: 9pt;"">1.1.</span><span style=""font-size: 7pt;"">\xa0\xa0</span><span style=""font-size: 9pt;"">Patient’s disease has had a complete response to treatment; or</span></p><p><span style=""font-size: 9pt;"">1.2.</span><span style=""font-size: 7pt;"">\xa0\xa0</span><span style=""font-size: 9pt;"">Patient’s disease has had a partial response to treatment; or</span></p><p><span style=""font-size: 9pt;"">1.3.</span><span style=""font-size: 7pt;"">\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has stable disease; and</span></p><p><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Response to treatment in target lesions has been determined by comparable radiologic assessment following the most recent treatment period; and</span></p><p><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">No evidence of disease progression; and</span></p><p><span style=""font-size: 9pt;"">4.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">The treatment remains clinically appropriate and patient is benefitting from treatment; and</span></p><p><span style=""font-size: 9pt;"">5.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">XXXX to be used at a maximum dose of XXX every XXX weeks (or equivalent); and</span></p><p><span style=""font-size: 9pt;"">6.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">XXXX to be discontinued at signs of disease progression; and</span></p><p><span style=""font-size: 9pt;"">7.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Treatment with XXXX to cease after a total duration of 24 months from commencement (or equivalent).</span></p>', 'Published_Application__c': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee reviewed the application from BeiGene NZ Unlimited for the use of tislelizumab (Tevimbra) for the second-line treatment of non-small cell lung cancer (NSCLC) which was received in response to Pharmac’s 2022 Request For Proposals (RFP) for immune checkpoint inhibitors (ICIs).</p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that Pharmac staff sought advice in the context of this RFP for ICIs for advanced NSCLC, noting that Pharmac has received previous advice regarding atezolizumab, nivolumab and pembrolizumab in this setting.</p><p>1.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee took into account, where applicable, Pharmac’s relevant decision-making framework when considering this agenda item.\xa0</p>', 'Published_Discussion__c': '<h3><em>Māori Impact</em></h3><p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that the disproportionate impact of advanced NSCLC for Māori had been described well in its previous considerations for agents for funding in this context. The Committee noted that Māori with any lung cancer have a very high health need and considered this was a particularly important gap to address.</p><h3><br></h3><h3><em>Background</em></h3><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the clinical advice and recommendations previously provided for the following ICIs for second-line treatment of NSCLC:</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://connect.pharmac.govt.nz/apptracker/s/application-public/a102P000008ptuw/p000243"" target=""_blank"">Atezolizumab (Tecentriq) for locally advanced or metastatic NSCLC after prior chemotherapy</a> (CaTSoP - Low August 2017; PTAC – Low August 2017)</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://connect.pharmac.govt.nz/apptracker/s/application-public/a102P000008puDw/p000793"" target=""_blank"">Nivolumab (Opdivo) for locally advanced or metastatic squamous and non-squamous NSCLC</a> (CaTSoP - Low/Medium April 2016; PTAC – Low May 2016)</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://connect.pharmac.govt.nz/apptracker/s/application-public/a102P000008puZ2/p001209"" target=""_blank"">Pembrolizumab (Keytruda) for locally advanced, or metastatic, unresectable NSCLC whose tumours express PD-L1 at a level of ≥ 1%</a> (PTAC – Low November 2016; CaTSoP – Low March 2017).</p><p>1.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the clinical trial evidence for each of these previously considered ICIs used docetaxel chemotherapy as a control and that this is the current standard of care in New Zealand for the second-line treatment of NSCLC.</p><h3><br></h3><h3><em>Health Need</em></h3><p>1.4.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the health need of this population and current treatment paradigm has been extensively discussed previously by PTAC and CTAC. Members considered that health need of this population remained very high and noted that international access to new treatments is increasing for all lines of NSCLC treatment.</p><p>1.5.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that Māori with any lung cancer have a very high health need, experiencing higher lung cancer registration and mortality rates than non-Māori, and considered this was a particularly important gap to address.</p><h3><br></h3><h3><em>Health Benefits and Suitability</em></h3><p>1.6.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that tislelizumab 100 mg/10mL concentrate for injection is currently being evaluated by Medsafe for oesophageal cancer and three NSCLC indications, including use as monotherapy for the treatment of patients with locally advanced or metastatic NSCLC after prior chemotherapy. The Committee noted that at the time of submission, the application was considered to meet Pharmac’s criteria for consideration under the <a href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/cancer-medicine-funding-parallel-assessment/"" target=""_blank"">parallel assessment</a> pathway, which provides for consideration of cancer medicines at the same time as they are assessed by Medsafe.</p><p>1.7.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the key evidence for tislelizumab for the second-line treatment of NSCLC comes from one key clinical trial, RATIONALE-303: a randomised (2:1), open-label, multi-centre, phase 3 study of 805 adults with histologically confirmed, locally advanced or metastatic NSCLC who had disease progression during or after a platinum-containing regimen. Participants received either tislelizumab 200 mg IV Q3W or docetaxel 75 mg/m2 IV Q3W until unacceptable toxicity or disease progression, and those in the tislelizumab arm had the option of subsequent tislelizumab 200 mg IV Q3W post-disease progression at the investigator’s discretion. The Committee noted that the following data from RATIONALE-303 was submitted for review:</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://ascopubs.org/doi/10.1200/JCO.2018.36.15_suppl.TPS3112"" target=""_blank"">Huang et al. J Clin Oncol. 2018; 36(15_Supplement)</a></p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://aacrjournals.org/cancerres/article/81/13_Supplement/CT039/669829/Abstract-CT039-Results-from-RATIONALE-303-A-global"" target=""_blank"">Zhou et al. Cancer Res. 2021; 81(13_Supplement):CT039</a></p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>RATIONALE-303 Clinical Study Report (CSR) 2022</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.beigenemedical.com/CongressDocuments/Zhou%20BGB-A317%20303%20PRO%20ASCO%20Poster%202021.pdf"" target=""_blank"">Zhou et al. J Clin Oncol. 2021;39(15_Supplement):9069</a></p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Fan et al. J Thorac Oncol. 2021;16:S1021</p><p>1.8.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that 80% of RATIONALE-303 participants were from China and that 14 (&lt;2%) of patients were enrolled in New Zealand. The Committee considered that patient characteristics were similar across treatment groups and although there were differences between the trial patient populations, it was not unreasonable to compare with the results of the second-line trials for atezolizumab, nivolumab and pembrolizumab. The Committee noted that about half of the RATIONALE-303 participants had non-squamous NSCLC and that large proportions of patients had unknown EGFR mutation (&gt;30%) or ALK rearrangement (&gt;50%) status. The Committee noted that for 15% of patients the trial treatment was a third-line therapy (ie had received two prior lines) and that disease progression was the most common reason for trial treatment discontinuation.</p><p>1.9.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the primary endpoint of RATIONALE-303 was overall survival (OS) in the intention-to-treat (ITT) and PD-L1 positive (≥25%) populations, which was reported after median 31.1 months and 27.9 months follow-up for the tislelizumab and docetaxel arms, respectively.</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the median OS in the ITT group was 16.9 months (95% CI: 15.24 to 19.09 months) with tislelizumab compared with 11.9 months (95% CI: 9.6 to 13.54 months) with docetaxel; hazard ratio (HR) for death: 0.66 (95% CI: 0.56 to 0.79; P&lt;0.0001). The Committee noted that the OS benefit with docetaxel appeared slightly better than that seen in the control arm of the studies previously considered for other ICIs for this indication, however, considered that this difference might be due to improvements in patient care and management of adverse events occurring in the years since the trials were initiated.</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that 29.5% of patients in the tislelizumab arm continued tislelizumab after radiographic progression, and that 20.4% of patients in the docetaxel arm subsequently received immunotherapy. The Committee considered that, although occurring in large proportions, this crossover and treatment beyond progression was unlikely to have a material impact on survival outcomes given the benefit seen despite the crossover. Members noted that the duration of treatment beyond progression was unknown but considered that in this disease, patients generally become symptomatic in a short time and then discontinue such treatment.</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that median OS in the PD-L1 positive group was 19.3 months with tislelizumab compared with 11.5 months with docetaxel; HR 0.53 (95% CI: 0.404 to 0.696; P&lt;0.0001). The Committee noted that the study assessed different PD-L1 thresholds and that the results indicated that all participants received a benefit regardless of PD-L1 expression.</p><p>1.10.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the duration of response (DOR) in the RATIONALE-303 ITT population, a secondary outcome, was a median of 13.5 months (95% CI: 8.54 to 19.58 months) with tislelizumab compared with 6.0 months (95% CI: 2.10 to 7.16 months) with docetaxel (HR 0.31; 95% CI: 0.176 to 0.536; P&lt;0.0001). The Committee considered this to be an important outcome for patients because a durable benefit leads to long-term benefits.</p><p>1.11.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the median progression-free survival (PFS) in RATIONALE-303 was 4.2 months (95% CI: 3.88 to 22.6 months) with tislelizumab compared with 2.6 months (95% CI: 2.2 to 3.8 months) with docetaxel; HR: 0.63 (95% CI: 0.53 to 0.75).</p><p>1.12.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that treatment-emergent adverse events led to discontinuation in about 12% of RATIONALE-303 participants in each arm. The Committee considered that there was a relatively high rate of grade three or higher immune-related adverse events (irAEs) in the tislelizumab arm, however, members considered this was similar to what would be expected based on the evidence and experience with other ICIs. The Committee noted that there were no new irAE signals with tislelizumab.</p><p>1.13.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the second-line clinical trial evidence for tislelizumab from RATIONALE-303 (including its statistical analyses) was not yet published or peer reviewed and considered its appraisal of the data was somewhat limited by this, however, the Committee considered this status was not surprising given that trial completion is expected in December 2022.</p><p>1.14.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted a cost-effectiveness analysis of tislelizumab relative to each nivolumab and docetaxel, as second- and third-line for advanced or metastatic non-small cell lung cancer in China (<a href=""https://www.frontiersin.org/articles/10.3389/fphar.2022.880280/full"" target=""_blank"">Zhou et al. Front Pharmacol. 2022;13:880280</a>), and was made aware of another cost-effectiveness analysis of tislelizumab vs docetaxel for previously treated NSCLC in China (<a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/35614942/"" target=""_blank"">Gong et al. Front Pharmacol. 2022;13:830380</a>).</p><p>1.15.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted there is longer-term evidence now published from the clinical trials previously considered for second-line use of atezolizumab, nivolumab, and pembrolizumab. The Committee noted that the pembrolizumab KEYNOTE-010 trial included a more limited population (PD-L1 positive ≥1%) than that of the other trials which did not restrict eligibility to PD-L1 positive participants. The Committee noted that across these trials there were small proportions of patients with EGFR mutations or ALK rearrangement, that about a third had ECOG performance status of zero, and that 75-80% were receiving trial treatment as a second-line therapy. The Committee considered that the longer-term evidence from these trials showed similar PFS, OS and durable benefits and reinforced the impression of the class effect consideration with these ICIs in the first-line treatment of NSCLC:</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.jto.org/article/S1556-0864(20)30802-9/fulltext"" target=""_blank"">Mazieres et al. J Thorac Oncol. 2021;16:140-50</a> - After 47.7 months follow-up in the Oak trial, the median OS was 13.3 months with atezolizumab vs 9.8 months with docetaxel; HR 0.78 (0.68 to 0.89; P&lt;0.0001).</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8078445/"" target=""_blank"">Borghaei et al. J Clin Oncol. 2021;39:723-33</a> – After 64.2 and 64.5 months follow-up in the Checkmate 057 and 017 trials, respectively, the median pooled OS for squamous and non-squamous 9.2 months (95% CI: 7.3 to 12.6) with nivolumab vs 6.0 months (95% CI: 5.1 to 7.3) with docetaxel; HR 0.62 (95% CI: 0.48 to 0.79).</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.sciencedirect.com/science/article/abs/pii/S1556086421021729"" target=""_blank"">Herbst et al. J Thorac Oncol. 2021;16:1718-32</a><em> </em>– After 67.4 months follow-up in KEYNOTE-010, the median OS was 11.8 months (95% CI: 10.4 to 13.1) with pembrolizumab vs 8.4 months (95% CI: 7.6 to 9.5) with docetaxel; HR for death 0.70 (95% CI: 0.61–0.80). 21 patients received second-course pembrolizumab and there was 22.2% crossover in the docetaxel arm.\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</p><p>1.16.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that there were no direct comparisons of ICIs for second-line treatment of NSCLC but considered that the evidence reported relatively consistent OS improvement across trials with these ICIs despite some differences in the patient populations within the trials. The Committee further considered that there was no evidence to suggest any ICI might be better tolerated or more efficacious than any other, and therefore a class effect was likely to exist for these ICIs including tislelizumab based on the evidence available in this setting. The Committee considered that tislelizumab would have similar ability to address the unmet need in New Zealand for the second-line use of an ICI and that the evidence for tislelizumab’s safety profile also suggested a class effect.</p><p>1.17.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that tislelizumab would not be expected to provide any additional health benefits or create any additional risks compared with other ICIs (ie atezolizumab, nivolumab and pembrolizumab) considered for second-line treatment of advanced NSCLC. The Committee noted that a similar duration of treatment, similar side effects and considered that a similar frequency of treatment would be expected.</p><p>1.18.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the three-weekly frequency of tislelizumab treatment and considered that this may differ from that of other ICIs for second-line treatment of advanced NSCLC which may also have options for longer dosing intervals (eg four- or six-weekly). The Committee was made aware of evidence for longer dosing intervals of pembrolizumab from pharmacology modelling and international guidelines in response to the COVID-19 pandemic (<a href=""https://linkinghub.elsevier.com/retrieve/pii/S1556-0864(22)00314-8"" target=""_blank"">Higashiyama et al. J Thorac Oncol. 2022;17:1227-32</a>; <a href=""https://linkinghub.elsevier.com/retrieve/pii/S1556-0864(22)00347-1"" target=""_blank"">Mountzios et al. J Thorac Oncol. 2022;17:1155-7</a>). Members noted the number of patients who experienced new irAEs was slightly higher than expected although considered it unclear whether this was caused by the dosing interval change as this as it was not a controlled trial, and on balance, considered the dosing intervals likely to be safe. The Committee considered that the impact on the health system would be determined by the chosen ICI and the level of comfort with using different dosing schedules.</p><p>1.19.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the stability of the ICI solutions for infusion (once diluted, if applicable) at 2-8°C ranged from 24 hours for tislelizumab and atezolizumab to four or seven days for pembrolizumab and nivolumab, respectively. The Committee considered that the ease of treatment delivery differed between these ICIs and that these could be important factors for New Zealanders in regard to inequities and access to treatment, particularly those living in rural areas.</p><p>1.20.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered it reasonable to have a maximum funded treatment duration of 24 months with an option to have ICI retreatment where no progression occurred while on ICI treatment, noting that most clinical trials with a two-year ICI treatment duration include an option for retreatment. Members considered that it would be difficult to delineate whether people with NSCLC receiving retreatment would be considered to have first- or second-line treatment as clinically this might be approached as first-line with late progression, indicating a good response to first-line treatment.</p><p>1.21.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that CTAC should review new evidence when it eventuates regarding ICI retreatment for NSCLC (ie where progression did not occur while on ICI treatment) or regarding ICI treatment beyond progression in NSCLC. The Committee acknowledged its previous view regarding this may be amenable to newer information becoming available to support retreatment or treatment beyond progression. The Committee noted that at this time, the evidence supporting retreatment came from small numbers of patients who initially received 24 months of pembrolizumab and were then retreated post-progression in the KEYNOTE-010 trial (<a href=""https://ascopubs.org/doi/10.1200/JCO.19.02446?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub%20%200pubmed"" target=""_blank"">Herbst et al. J Clin Oncol. 2020;38:1580-90</a>) or patients who received 12 months of durvalumab and then treatment with durvalumab at progression in the PACIFIC trial (<a href=""https://ascopubs.org/doi/10.1200/JCO.21.01308?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub%20%200pubmed"" target=""_blank"">Spigel et al. J Clin Oncol. 2022;40:1301-11</a>).</p><h3><br></h3><h3><em>Costs and Savings</em></h3><p>1.22.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that if an ICI were funded for both first- and second-line treatment of NSCLC (but as a single line of treatment), that initially a large number of individuals would receive this as second-line ICI treatment, although this would reduce over time as first-line ICI therapy became common. The Committee considered that changes in health-sector expenditure with tislelizumab would be comparable to those with other ICIs for second-line treatment of advanced NSCLC but that there could be wastage associated with the reduced stability of tislelizumab as currently stated.</p><p>1.23.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that a two-year maximum treatment duration was appropriate to include in the PICO for assessment, noting its previous comments regarding the option for retreatment in only a small number of patients.</p><h3><br></h3><h3><em>Special Authority Criteria</em></h3><p>1.24.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that Special Authority criteria for an ICI (such as tislelizumab) for second-line treatment of NSCLC should:</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Target individuals with ECOG performance status of zero to two instead of zero to one, as most have ECOG of two after progression and would be considered able to tolerate this treatment.</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Not require documentation confirming that the disease does not express activating mutations of EGFR or ALK as this might create a barrier to access due to reliance on biopsy for tissue testing, and that such a criterion should be pragmatic and equitable.</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Omit the requirement for the use of RECIST for assessment, as this onerous assessment is difficult to do in the current health system constraints. Members considered that RECIST is not an ideal measure for lung tumour burden, that radiologist availability and cost are factors which can create barriers, and that it is challenging to have consistent assessment. However, the Committee noted the need to document disease burden at baseline to enable subsequent assessment.</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Require confirmation that there is no evidence of disease progression at renewal, and that it would be important that the same modality was used to establish response to treatment.</p><h3><br></h3><h3><em>Summary for Assessment</em></h3><p>1.25.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that the evidence for tislelizumab as second-line treatment of NSCLC was limited but not poor and that, for the purposes of economic modelling, it would be appropriate to assume that tislelizumab provided the same or similar health benefit to other agents currently under consideration.</p><p>1.26.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that the proportion of people who receive docetaxel in the second- and third-line setting was likely to be closer to 30%, rather than the current estimate of 50%.</p><p>1.27.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that the table below summarises its interpretation of the most appropriate PICO (population, intervention, comparator, outcomes) information for tislelizumab if it were to be funded in New Zealand for second-line treatment of NSCLC. This PICO captures key clinical aspects of the proposal and may be used to frame any future economic assessment by Pharmac staff. This PICO is based on the Committee’s assessment at this time and may differ from that requested by the applicant. The PICO may change based on new information, additional clinical advice, or further analysis by Pharmac staff.\xa0\xa0</p><p><img src=""/apptracker/servlet/rtaImage?eid=a0POZ00000FSxUO&amp;feoid=00N2P000000YsIc&amp;refid=0EM2P000002eNWd"" alt=""image.png""></img></p>', 'Status_History__c': 'a132P000000EDPDQA4'}, 'change': None}]",Jul 2022,False,True
2,"<p>Following Clinical Advice, Pharmac staff considers the advice and the funding application under goes an assessment using our&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/factors-for-consideration/"" rel=""nofollow"">Factors for Consideration</a>&nbsp;framework and seeks additional information as required.</p>
<p>&nbsp;</p>
<p>Research and Economic analysis are undertaken.&nbsp; This focuses on the costs and benefits of a proposed course of action. Economics is based on three fundamental concepts that summarise the issues Pharmac faces daily:&nbsp;</p>
<ul>
<li>Scarcity &ndash; resources will always be insufficient to support all possible activities.</li>
<li>Choices &ndash; due to scarce resources, decisions must be made about how best to use them.</li>
<li>Opportunity cost &ndash; by choosing to use resources one way, we forgo other opportunities to use the same resources.</li>
</ul>
<p>&nbsp;</p>
<p>For further information on the purpose of, and techniques for, undertaking economic analysis in health care, please refer&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/</a></p>",2,Under Assessment,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Sep 2024', 'fs': 'Sep 2024', 'change': None}, 'Event_Description': {'s': 'Working to compare options', 'fs': 'Working to compare options', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ00000FSxUQ2A1'}, 'Id': 'a0POZ00000FSxUQ2A1', 'Event_Date__c': '2024-09-25', 'Event_Description__c': 'Working to compare options', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'Sep 2024', 'Status_History__c': 'a13OZ00000EbZuqYAF'}, 'change': None}]",Sep 2024,False,True
3,"<p>Pharmac staff uses a prioritisation process to compare and rank funding options. Possible opportunities for new investment will always exceed the budget Pharmac has available; therefore, prioritisation is an intrinsic part of Pharmac’s decision-making process.</p>
<p>The relative ranking of options aims to support Pharmac&rsquo;s statutory objective &ldquo;to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided&rdquo;.</p>
<p>A funding application or proposal is considered ready for prioritisation when sufficient information is available to permit it to be reviewed against Pharmac's Factors for Consideration and to inform a comparison with other possible investment decisions.</p>
<p>There is no guarantee when or if a ranked medicine will be funded.&nbsp;&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/</a></p>",3,Options Compared,False,"[{'Summary': {'s': '<p><span style=""font-size: 16px;"">Atezolizumab is funded from 1 April 2023 as the only listed immune checkpoint inhibitor for the second line treatment of advanced NSCLC in New Zealand until at least 31 March 2026.</span></p>', 'fs': '<p><span style=""font-size: 16px;"">Atezolizumab is funded from 1 April 2023 as the only listed immune checkpoint inhibitor for the second line treatment of advanced NSCLC in New Zealand until at least 31 March 2026.</span></p>', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2023-03-07-decision-to-fund-two-new-treatments-for-people-with-advanced-non-small-cell-lung-cancer/"" target=""_blank"">Notification Letter</a></p>', 'fs': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2023-03-07-decision-to-fund-two-new-treatments-for-people-with-advanced-non-small-cell-lung-cancer/"" target=""_blank"">Notification Letter</a></p>', 'change': None}, 'Formatted_Date': {'s': 'Mar 2023', 'fs': 'Mar 2023', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ00000FSxUP2A1'}, 'Id': 'a0POZ00000FSxUP2A1', 'Event_Date__c': '2023-03-06', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Links__c': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2023-03-07-decision-to-fund-two-new-treatments-for-people-with-advanced-non-small-cell-lung-cancer/"" target=""_blank"">Notification Letter</a></p>', 'Summary__c': '<p><span style=""font-size: 16px;"">Atezolizumab is funded from 1 April 2023 as the only listed immune checkpoint inhibitor for the second line treatment of advanced NSCLC in New Zealand until at least 31 March 2026.</span></p>', 'Formatted_Date__c': 'Mar 2023', 'Status_History__c': 'a13OZ0000010h64YAA'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Sep 2024', 'fs': 'Sep 2024', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ00000FSxUR2A1'}, 'Id': 'a0POZ00000FSxUR2A1', 'Event_Date__c': '2024-09-25', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Sep 2024', 'Status_History__c': 'a13OZ00000EbsoBYAR'}, 'change': None}]",Mar 2023,False,True
4,"<p>Pharmac is consulting on a proposal to either approve or decline the application.&nbsp;We seek the views of all people who have an interest in our proposals, or who may be affected by them, to obtain feedback on our proposed approaches.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/</a></p>",4,Under Consultation,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/proposal-to-decline-inactive-applications-oct24"" target=""_blank"">Consultation</a></p>', 'fs': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/proposal-to-decline-inactive-applications-oct24"" target=""_blank"">Consultation</a></p>', 'change': None}, 'Formatted_Date': {'s': 'Oct 2024', 'fs': 'Oct 2024', 'change': None}, 'Event_Description': {'s': 'Public consultation for this application is active.', 'fs': 'Public consultation for this application is active.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ00000FSxUS2A1'}, 'Id': 'a0POZ00000FSxUS2A1', 'Event_Date__c': '2024-10-17', 'Event_Description__c': 'Public consultation for this application is active.', 'Stage__c': 'Under Consultation', 'Links__c': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/proposal-to-decline-inactive-applications-oct24"" target=""_blank"">Consultation</a></p>', 'Formatted_Date__c': 'Oct 2024', 'Status_History__c': 'a13OZ00000FTwJMYA1'}, 'change': None}]",Oct 2024,False,True
5,"<p>Following the consultation process, Pharmac staff considers the feedback and identifies any additional information required as part of a gap analysis.&nbsp; The proposal may require further clinical advice, research, and assessment.</p>",5,Reviewing Consultation Feedback,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Nov 2024', 'fs': 'Nov 2024', 'change': None}, 'Event_Description': {'s': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'fs': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ00000FSxUT2A1'}, 'Id': 'a0POZ00000FSxUT2A1', 'Event_Date__c': '2024-11-30', 'Event_Description__c': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'Stage__c': 'Reviewing Consultation Feedback', 'Formatted_Date__c': 'Nov 2024', 'Status_History__c': 'a13OZ00000HCoH6YAL'}, 'change': None}]",Nov 2024,False,True
6,"<p>We refer to our decisions about whether and how particular pharmaceuticals are publicly-funded, as &ldquo;funding decisions&rdquo;.</p>
<p>We consider and assess all funding decisions using the&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/about/operating-policies-and-procedures/#factorsfc"" rel=""nofollow"">Factors for Consideration</a>. When we do so, we carefully evaluate clinical and other evidence for the benefits and suitability of a proposal, and to identify and understand the people who will be affected by it.</p>
<p>While our main task is to allocate pharmaceutical funding, we consider the benefits and costs across the whole health system now and with a long-term focus, including the effects for hospitals and primary care, and consider direct costs to patients as well as to all health sector budgets.</p>
<p>Final funding decisions are made by the Pharmac Board or delegated to senior Pharmac staff as required by the Board.</p>
<p>&nbsp;</p>",6,Decision,True,,,False,False
